Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device VC activity

This article was originally published in The Gray Sheet

Executive Summary

Investors closed 95 deals in the sector worth $755 million during the second quarter of 2010, a 40% increase in both dollars and deals over the first quarter, according to the latest MoneyTree report from PricewaterhouseCoopers LLP and the National Venture Capital Association. In the first quarter, device companies generated 68 deals valued at nearly $539.6 million. Biotechnology received the highest level of funding of all sectors, attracting $1.3 billion for 139 deals, up 59%. The report, which uses data from Thomson Reuters, said that venture capitalists over the period invested $6.5 billion in 906 deals in all sectors combined

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel